Egalet Corp (EGLT) 6.79 $EGLT
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.50 (-0.34), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), AXN: 0.28 (-0.01), SRNE: 4.65 (+0.05), NKTR: 13.35 (-0.21), EGLT: 6.79 (-0.05), AZN: 72.88 (+0.03), VBAY: ()
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
GlobeNewswire - Wed Nov 05, 7:30AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:10 p.m. EST. The conference will be held at the New York Palace Hotel.
EGLT: 6.79 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
VTNR: 6.19 (+0.43), EGLT: 6.79 (-0.05), BRDR: 7.00 (-0.04), ALIM: 5.06 (-0.04), ACHN: 10.11 (-0.15), VLCCF: 7.92 (+0.49), REXX: 8.00 (+0.50), FNHC: 26.14 (+0.04), ARCP: 8.79 (+0.15), CKEC: 27.90 (-0.17), PCLN: 1,094.61 (-3.14)
Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November 12, 2014
PR Newswire - Wed Oct 29, 7:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today announced that its third quarter financial results will be released on Wednesday, November 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update.
EGLT: 6.79 (-0.05)
2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 6.39 (-0.14), EGLT: 6.79 (-0.05)
Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:46AM CDT
Egalet (EGLT) was a big mover last session, with shares rising over 7% on the day.
LCI: 50.17 (-0.82), EGLT: 6.79 (-0.05), SHPG: 198.58 (-1.37), CEMP: 13.76 (-0.24)
Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001
GlobeNewswire - Tue Sep 23, 3:00PM CDT
Egalet Corporation (Nasdaq:EGLT) (Egalet) today announced an update to the clinical development plan for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Based on the clinical data generated thus far, the Company will need to conduct additional clinical trials to strengthen the new drug application (NDA) for Egalet-001. Egalet plans to schedule a meeting in the fourth quarter of 2014 with the U.S. Food and Drug Administration (FDA) to discuss the totality of the clinical data from the studies completed and the appropriate registration path forward for Egalet-001.
EGLT: 6.79 (-0.05)
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
GlobeNewswire - Thu Sep 11, 7:13AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's product candidates and the Company's proprietary Guardian Technology. The following patents were issued:
EGLT: 6.79 (-0.05)
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, at PAINWeek 2014 in Las Vegas September 2 to 6.
EGLT: 6.79 (-0.05)
Falling Earnings Estimates Signal Weakness Ahead for Egalet (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:46AM CDT
Egalet has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
ENDP: 68.96 (-1.23), EGLT: 6.79 (-0.05), UTHR: 124.21 (-1.12), HPTX: 21.82 (-1.83)
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
EGLT: 6.79 (-0.05)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.50 (-0.34), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), AXN: 0.28 (-0.01), SRNE: 4.65 (+0.05), NKTR: 13.35 (-0.21), EGLT: 6.79 (-0.05), AZN: 72.88 (+0.03), VBAY: ()
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
GlobeNewswire - Wed Nov 05, 7:30AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:10 p.m. EST. The conference will be held at the New York Palace Hotel. EGLT: 6.79 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
VTNR: 6.19 (+0.43), EGLT: 6.79 (-0.05), BRDR: 7.00 (-0.04), ALIM: 5.06 (-0.04), ACHN: 10.11 (-0.15), VLCCF: 7.92 (+0.49), REXX: 8.00 (+0.50), FNHC: 26.14 (+0.04), ARCP: 8.79 (+0.15), CKEC: 27.90 (-0.17), PCLN: 1,094.61 (-3.14)
Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November 12, 2014
PR Newswire - Wed Oct 29, 7:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today announced that its third quarter financial results will be released on Wednesday, November 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. EGLT: 6.79 (-0.05)
2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 6.39 (-0.14), EGLT: 6.79 (-0.05)
Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:46AM CDT
Egalet (EGLT) was a big mover last session, with shares rising over 7% on the day.
LCI: 50.17 (-0.82), EGLT: 6.79 (-0.05), SHPG: 198.58 (-1.37), CEMP: 13.76 (-0.24)
Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001
GlobeNewswire - Tue Sep 23, 3:00PM CDT
Egalet Corporation (Nasdaq:EGLT) (Egalet) today announced an update to the clinical development plan for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Based on the clinical data generated thus far, the Company will need to conduct additional clinical trials to strengthen the new drug application (NDA) for Egalet-001. Egalet plans to schedule a meeting in the fourth quarter of 2014 with the U.S. Food and Drug Administration (FDA) to discuss the totality of the clinical data from the studies completed and the appropriate registration path forward for Egalet-001.
EGLT: 6.79 (-0.05)
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
GlobeNewswire - Thu Sep 11, 7:13AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's product candidates and the Company's proprietary Guardian Technology. The following patents were issued: EGLT: 6.79 (-0.05)
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, at PAINWeek 2014 in Las Vegas September 2 to 6. EGLT: 6.79 (-0.05)
Falling Earnings Estimates Signal Weakness Ahead for Egalet (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:46AM CDT
Egalet has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
ENDP: 68.96 (-1.23), EGLT: 6.79 (-0.05), UTHR: 124.21 (-1.12), HPTX: 21.82 (-1.83)
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. EGLT: 6.79 (-0.05)
